Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Raphael

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 17, 2020
Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditisShira Peleg Hasson, Benjamin Salwen, Ayelet Sivan, et al.
Journal of Clinical Medicine|May 14, 2022
<i>FGFR</i> Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)Ari Raphael, Elizabeth Dudnik, Dov Hershkovitz, et al.
Frontiers in Oncology|June 1, 2022
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2<sup>nd</sup>/3<sup>rd</sup>-Generation ALK Tyrosine Kinase Inhibitors (TKIs)Ari Raphael, Amir Onn, Liran Holtzman, et al.
The Oncologist|June 28, 2025
The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitorsMoran Gvili Perelman, Rafael Y Brzezinski, Barliz Waissengrin, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 17, 2020
Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditisShira Peleg Hasson, Benjamin Salwen, Ayelet Sivan, et al.
Journal of Clinical Medicine|May 14, 2022
<i>FGFR</i> Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)Ari Raphael, Elizabeth Dudnik, Dov Hershkovitz, et al.
Frontiers in Oncology|June 1, 2022
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2<sup>nd</sup>/3<sup>rd</sup>-Generation ALK Tyrosine Kinase Inhibitors (TKIs)Ari Raphael, Amir Onn, Liran Holtzman, et al.
The Oncologist|June 28, 2025
The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitorsMoran Gvili Perelman, Rafael Y Brzezinski, Barliz Waissengrin, et al.
Pageof 2